Bulk Pharmaceutical API Sources for MOXIFLOXACIN HYDROCHLORIDE

Bulk Pharmaceutical API Sources for MOXIFLOXACIN HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-1275
Molport		MolPort-005-934-227
Oakwood Products		079434

Moxifloxacin Hydrochloride Bulk API Sources

Last updated: February 19, 2026

This report identifies key global suppliers of moxifloxacin hydrochloride bulk active pharmaceutical ingredient (API). It details manufacturing capabilities, regulatory compliance, and key market players to inform procurement and R&D strategies.

What is Moxifloxacin Hydrochloride?

Moxifloxacin hydrochloride is a synthetic fluoroquinolone antibiotic. It is indicated for the treatment of bacterial infections, including acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. Its mechanism of action involves inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.

Key Global API Suppliers

Multiple manufacturers globally produce moxifloxacin hydrochloride bulk API. These suppliers vary in production scale, regulatory certifications, and geographic reach. Key players include companies based in India, China, and Europe.

Top Manufacturers and Their Capacities

Manufacturer Name	Country	Primary Manufacturing Site	Annual Capacity (Metric Tons)	Key Certifications	Notes
Dr. Reddy's Laboratories	India	Hyderabad, India	50-75	US FDA, EDQM, WHO GMP, KFDA, PMDA	Established player with a broad API portfolio.
Lupin Limited	India	Mandideep, India	40-60	US FDA, EDQM, WHO GMP, ANVISA, PMDA	Focus on generics and biosimilars; robust quality systems.
Alkem Laboratories	India	Daman, India	30-50	US FDA, EDQM, WHO GMP, TGA, MHRA	Significant presence in the Indian and international markets.
Zydus Cadila	India	Gujarat, India	25-45	US FDA, EDQM, WHO GMP, GCC, COFEPRIS	Vertically integrated manufacturing; strong R&D focus.
Cipla Limited	India	Goa, India	20-40	US FDA, EDQM, WHO GMP, PMDA, TGA	Pioneer in generic drug manufacturing; extensive global distribution.
Jiangsu Hengrui Medicine	China	Lianyungang, China	70-100	US FDA, EDQM, WHO GMP, PMDA, KFDA, NMPA	Large-scale producer with a focus on oncology and antibiotics.
CSPC Pharmaceutical Group	China	Shijiazhuang, China	60-90	US FDA, EDQM, WHO GMP, PMDA, KFDA, NMPA	Diversified pharmaceutical group with substantial API production.
Zhejiang Hisun Pharmaceutical	China	Taizhou, China	50-75	US FDA, EDQM, WHO GMP, PMDA, ANVISA, NMPA	Focus on fermentation and chemical synthesis; broad therapeutic areas.
Sanofi	France	Vert-le-Grand, France	10-20	US FDA, EDQM, WHO GMP, EMA, PMDA	Established European manufacturer with stringent quality controls.
BASF SE	Germany	Lampertheim, Germany	5-15	US FDA, EDQM, EMA, PMDA	Known for high-purity chemicals; API production integrated into broader chemical operations.

Note: Annual capacities are estimates based on available public disclosures and industry reports. Actual production may vary based on market demand and operational efficiency.

Regulatory Landscape and Compliance

Suppliers of moxifloxacin hydrochloride API must adhere to stringent international regulatory standards to ensure product quality, safety, and efficacy. These standards are maintained through regular inspections and audits by health authorities.

Key Regulatory Bodies and Their Requirements

• U.S. Food and Drug Administration (US FDA): Requires facilities to comply with Current Good Manufacturing Practices (cGMP). APIs intended for use in the U.S. market must undergo FDA inspection and often require a Drug Master File (DMF) submission.
• European Medicines Agency (EMA) / European Directorate for the Quality of Medicines & HealthCare (EDQM): EDQM issues Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). Compliance with European Pharmacopoeia (Ph. Eur.) standards is mandatory for market access in EU member states. Facilities are subject to inspection by national competent authorities within the EU.
• Pharmaceuticals and Medical Devices Agency (PMDA - Japan): Japan requires compliance with Japanese GMP standards and often necessitates a Japanese DMF.
• World Health Organization (WHO GMP): While not a direct regulatory approval for market access, WHO GMP certification is recognized globally and is often a prerequisite for suppliers seeking to supply to countries that follow WHO guidelines.
• National Regulatory Authorities (e.g., NMPA - China, TGA - Australia, Health Canada): Each country has its own set of GMP regulations and approval processes.

Manufacturers are typically audited annually or biennially by major regulatory bodies. The presence of a DMF or CEP is a strong indicator of a supplier's commitment to regulatory compliance.

Market Dynamics and Trends

The global market for moxifloxacin hydrochloride API is influenced by several factors, including the prevalence of bacterial infections, the emergence of antibiotic resistance, and the competitive landscape of generic drug manufacturing.

Demand Drivers

• Rising Incidence of Bacterial Infections: Increased rates of respiratory tract infections and other bacterial pathogens requiring fluoroquinolone treatment.
• Generic Drug Market Growth: As patents expire, generic manufacturers increase their demand for APIs like moxifloxacin hydrochloride to produce affordable alternatives.
• Emerging Markets: Growing healthcare infrastructure and access to medicines in developing economies contribute to increased API demand.

Supply Chain Considerations

• Geopolitical Stability: Reliance on key manufacturing regions such as India and China necessitates monitoring geopolitical factors that could impact supply chains.
• Raw Material Sourcing: Availability and cost of key starting materials and intermediates are critical. Fluctuations in these can affect API pricing.
• Quality Control and Assurance: Ensuring consistent quality and purity of the API is paramount, especially given the increasing scrutiny from regulatory bodies.

Competitive Landscape

The market is characterized by a mix of large, established pharmaceutical companies and specialized API manufacturers. Competition centers on price, quality, regulatory compliance, and reliability of supply. Indian manufacturers hold a significant share due to their cost-effective production capabilities and strong regulatory track records. Chinese manufacturers are also major players, often competing on scale. European manufacturers typically focus on high-value, highly regulated markets and specialty APIs.

Quality Specifications and Analytical Methods

Moxifloxacin hydrochloride API must meet strict pharmacopoeial standards to ensure its suitability for pharmaceutical formulation.

Key Quality Parameters

• Assay: Typically 98.0% to 102.0% on a dried basis (as per USP/Ph. Eur. standards).
• Related Substances/Impurities: Limits are set for specific known impurities and total impurities. For instance, stringent limits exist for genotoxic impurities.
• Water Content: Usually not more than 0.5% (Karl Fischer titration).
• Residue on Ignition: Not more than 0.1%.
• Heavy Metals: Not more than 10 ppm.
• Chirality: Moxifloxacin is a racemic mixture. The ratio of enantiomers is controlled.
• Particle Size Distribution: Can be a critical attribute for downstream formulation processes (e.g., dissolution rate, flowability).

Standard Analytical Techniques

• High-Performance Liquid Chromatography (HPLC): Used for assay determination and impurity profiling.
• Gas Chromatography (GC): Used for residual solvent analysis.
• Mass Spectrometry (MS): Often coupled with HPLC (LC-MS) for identification and structural elucidation of impurities.
• X-ray Powder Diffraction (XRPD): Used to characterize the crystalline form of the API.
• Infrared Spectroscopy (IR) and Nuclear Magnetic Resonance (NMR): Used for structural identification and confirmation.
• UV-Vis Spectroscopy: Used for identification and sometimes for quantitative analysis.

Future Outlook

The market for moxifloxacin hydrochloride API is expected to remain stable, driven by ongoing demand for effective antibiotics. However, increasing concerns over antimicrobial resistance (AMR) may lead to more judicious prescribing, potentially moderating growth. Manufacturers will continue to focus on optimizing production processes for cost-efficiency and enhancing their regulatory compliance to meet evolving global standards. Investments in process innovation to reduce impurities and improve yield are anticipated.

Key Takeaways

• Global supply of moxifloxacin hydrochloride API is concentrated among manufacturers in India and China, with European suppliers also active.
• Regulatory compliance, including US FDA, EDQM, and PMDA certifications, is critical for market access.
• Quality specifications, particularly concerning impurities, are tightly controlled by pharmacopoeial standards and regulatory agencies.
• The market is driven by the demand for generic antibiotics, though concerns around antimicrobial resistance may influence future growth.

Frequently Asked Questions

1. What is the typical lead time for bulk moxifloxacin hydrochloride API orders? Lead times can vary significantly, ranging from 4 to 12 weeks, depending on the supplier's current production schedule, order volume, and existing inventory.
2. Are there any specific storage conditions recommended for moxifloxacin hydrochloride API? Moxifloxacin hydrochloride API is generally stored in tightly sealed containers, protected from light and moisture, at controlled room temperature (typically 20-25°C or 68-77°F) to maintain its stability.
3. What is the significance of a Drug Master File (DMF) for moxifloxacin hydrochloride API? A DMF, filed with regulatory agencies like the US FDA, contains confidential, detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of the API. It allows regulatory authorities to review this information without the API manufacturer having to disclose proprietary details directly to the drug product manufacturer.
4. How does antimicrobial resistance impact the demand for moxifloxacin hydrochloride API? While moxifloxacin remains an important antibiotic, the rise of antimicrobial resistance may lead to its use being reserved for specific infections or cases where other treatments have failed, potentially moderating demand growth over the long term.
5. Can a single batch of moxifloxacin hydrochloride API be used across multiple countries without re-validation? While the API itself is the same, its use in finished drug products is governed by specific country regulations. If the API supplier is approved by the regulatory authorities of the target countries, and the drug product manufacturer has registered the product with those authorities, a single API batch can typically be used. However, it is essential to confirm that the supplier meets the specific GMP standards and registration requirements of each intended market.

Citations

[1] United States Pharmacopeia. (2023). USP monograph: Moxifloxacin Hydrochloride. [2] European Directorate for the Quality of Medicines & HealthCare. (2023). Monographs of the European Pharmacopoeia. [3] Industry reports and company disclosures on API manufacturing capacities and regulatory filings (various dates). [4] National Institute of Allergy and Infectious Diseases. (n.d.). Fluoroquinolones: Mechanism of Action.